Abstract: Provided herein are compositions and methods for quantifying polyphosphates. In particular, provided herein are solution and substrate based assays for quantifying polyphosphates in complex samples.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: Methods for stopping or slowing bleeding from a wound are provided; these methods include the step of administering a composition comprising a polyphosphate (polyP) to blood from the wound at the site of the wound. Also provided are methods for slowing fibrinolysis and for blocking the action of Tissue Factor Pathway Inhibitor (TFPI) with the use of polyP.

Abstract: A sharing application for equipment, materials, and/or personnel is disclosed. A method for obtaining use, by a recipient, of an asset made available by a supplier on an asset sharing platform may include receiving first data comprising one or more criteria associated with a desired asset and an indication of a planned usage of the desired asset, wherein the desired asset comprises one or more of a heavy machine, a heavy machine implement, and a service relating to heavy machines. Second data may be received comprising at least one of data associated with the recipient, data associated with a plurality of suppliers, and data associated with a plurality of available assets. The method may further include causing display of an asset listing comprising identifications of one or more assets of the plurality of available assets, the displayed asset listing determined based, at least, on the first data and the second data.

Abstract: A sodium-ion battery includes a cathode comprising sodium; and an anode composition comprising a material having the formula: AaBbCcDdO, where A is an alkali metal, alkaline earth metal, or a combination thereof, where B is titanium, C is vanadium, D is one or more transition metal element other than titanium or vanadium, a+b+c+d?1, a?0, b+c>0, b?0, c?0, d>0, and where the material comprises a ilmenite structure, triclinic VFeO4 structure, cubic Ca5Co4(VO4)6 structure, dichromate structure, orthorhombic ?-CoV3O8 structure, brannerite structure, thortveitite structure, orthorhombic ?-CrPO4 structure, or the pseudo rutile structure.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

Abstract: The invention herein disclosed provides for compositions, methods for synthesizing said compositions, and methods for using said compositions, wherein the compositions and methods may be used in clinical treatment using hematopoietic transplantation, particularly to those relating to treatment of cancer and metastasis. The compositions regulate mobilization of hematopoietic stem cells (HSCs) between bone marrow (BM) and the peripheral blood (PB).

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application.

Abstract: A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

Abstract: A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.

Abstract: A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application.

Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.

Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.

Abstract: One or more voice mail messages, respectively, may be provided as one or more reminder messages. After the playing of a voice mail message, an option may be provided to use the message as a reminder message. Delivery information for the reminder message is obtained. The delivery information may include the user's telephone number, another telephone number, multiple telephone numbers, or identifiers for other devices. The delivery information also may include a designated time for delivery or different times for each of the destinations. The delivery of the reminder message may be password protected. The reminder message is delivered based on the delivery information. If the reminder message is password protected, the reminder message is delivered in response to receipt of the password.

Abstract: The present invention provides crystalline molecules and molecular complexes that comprise binding pockets of Sykcat and its homologues. The invention also provides crystals comprising the catalytic domain of Syk protein. The invention further provides a computer comprising a data storage medium encoded with the structure coordinates of Sykcat binding pockets and methods for using a computer to evaluate the ability of a chemical entity or compounds to bind to a crystalline molecule or molecular complex of the invention. This invention also provides methods of using the structure coordinates to solve the structure homologous proteins or protein complexes. The invention further provides methods of using the structure coordinates to screen for, design and optimize chemical entities or compounds, including inhibitory compounds, that bind to the catalytic domain of Syk or homologues thereof.

Abstract: A thromboplastin reagent includes tissue factor, Factor VIIa, and a net negatively charged phospholipid. The thromboplastin reagent is a synthetic thromboplastin reagent, and is in dried form.